AnaptysBio (NASDAQ:ANAB) Stock Rating Lowered by Wall Street Zen

AnaptysBio (NASDAQ:ANAB) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Sunday, Wall Street Zen reports.

Several other research analysts have also recently commented on the stock. Scotiabank cut shares of AnaptysBio to a “hold” rating and set a $70.00 target price for the company. in a report on Tuesday, August 25th. HC Wainwright restated a “buy” rating and set a $95.00 price target on shares of AnaptysBio in a report on Tuesday, September 22nd. JPMorgan Chase & Co. reduced their price target on shares of AnaptysBio from $70.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, September 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a research note on Friday, August 7th. Finally, TD Cowen lowered their price objective on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, August 25th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus price target of $77.79.

AnaptysBio Stock Up 1.4%

Shares of NASDAQ ANAB opened at $49.20 on Friday. AnaptysBio has a 12 month low of $19.65 and a 12 month high of $72.36. The company has a market cap of $1.47 billion, a price-to-earnings ratio of 9.16 and a beta of 0.76. The business has a fifty day simple moving average of $54.95 and a 200-day simple moving average of $58.45.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $5.57. The business had revenue of $27.49 million during the quarter, compared to analyst estimates of $14.06 million. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%.During the same quarter last year, the company posted ($1.30) EPS. As a group, sell-side analysts expect that AnaptysBio will post -1.3 EPS for the current fiscal year.

Insiders Place Their Bets

In other AnaptysBio news, Director Hollings Renton sold 5,000 shares of AnaptysBio stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $49.87, for a total transaction of $249,350.00. Following the transaction, the director owned 10,995 shares of the company’s stock, valued at $548,320.65. The trade was a 31.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 31.50% of the stock is currently owned by company insiders.

Institutional Trading of AnaptysBio

A number of hedge funds have recently made changes to their positions in ANAB. Persistent Asset Partners Ltd purchased a new position in AnaptysBio during the second quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd lifted its position in AnaptysBio by 940.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after buying an additional 1,383 shares in the last quarter. Group One Trading LLC acquired a new stake in shares of AnaptysBio during the 2nd quarter valued at $140,000. State of Wyoming acquired a new stake in shares of AnaptysBio during the 2nd quarter valued at $158,000. Finally, E Fund Management Co. Ltd. purchased a new position in shares of AnaptysBio during the 2nd quarter valued at $208,000.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for inflammatory and autoimmune diseases. The company uses its antibody discovery and engineering capabilities to identify therapies designed to modulate immune-system targets involved in disease.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to target CD200R1, a receptor involved in regulating immune-cell activity. The company has evaluated rosnilimab in inflammatory and autoimmune conditions, including rheumatoid arthritis and ulcerative colitis.